Improved patient outcomes through dosage individualisation of the newer immunosuppressant drugs

通过新型免疫抑制剂的剂量个体化改善患者的治疗效果

• 批准号: nhmrc : 511109
• 负责人: Dr Christine Staatz
• 金额: $ 32.42万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improved-patient-outcomes-immunosuppressant-drugs/94437
• 关键词: Improved; patient; outcomes; through; dosage

After organ transplantation, recipients need to take medicines continually to stop their immune system from rejecting their new organ. This treatment with immunosuppressant drugs is vital for long-term success of their graft. However, too many people are losing their transplant or are experiencing drug toxicity or infection due to poorly managed immunosuppression. The project aims to accurately define the best way to dose newer immunosuppressant drugs in Australian transplant populations.

器官移植后，接受者需要不断服用药物，以阻止他们的免疫系统排斥他们的新器官。免疫抑制药物的治疗对于移植的长期成功至关重要。然而，太多的人失去了他们的移植或正在经历药物毒性或感染，由于管理不善的免疫抑制。该项目旨在准确确定在澳大利亚移植人群中使用新型免疫抑制剂的最佳方法。